Industrially viable and advantageous processes for the preparation of Ozanimod are described. The invention also discloses the intermediates obtained in the process.

##STR00001##

One aspect is contemplated for providing a device having a liquid crystal material exhibiting a dielectric constant of 1000 or more at a temperature at which a specific liquid crystal phase is developed, and a unit configured to apply voltage to the liquid crystal material at the temperature at which the specific liquid crystal phase is developed.

One aspect is contemplated for providing a device having a liquid crystal material exhibiting a dielectric constant of 1000 or more at a temperature at which a specific liquid crystal phase is developed, and a unit configured to apply voltage to the liquid crystal material at the temperature at which the specific liquid crystal phase is developed.

A polarizing plate protective film which prevents deterioration of polarization performance in a high temperature, high humidity environment, and a polarizing plate and display device using the film including a compound represented by the following General Formula (I).

(X-L.sub.nz  General Formula (I)

X represents a formyl group, a boronic acid group, or a group represented by the following General Formula (I-B) or a group represented by the following General Formula (I-C), where L represents a single bond or divalent linking group, and n represents an integer equal to or greater than 2. When n is 2, Z represents a single bond or a divalent group, and when n≧3, Z represents an n-valent group.

##STR00001##

R.sup.A and R.sup.B represent an alkyl group, a cycloalkyl group, an aryl group, or an acyl group. R.sup.A and R.sup.B may be bonded to each other to form a ring. * represents a bond to be bonded to L.

A polarizing plate protective film which prevents deterioration of polarization performance in a high temperature, high humidity environment, and a polarizing plate and display device using the film including a compound represented by the following General Formula (I).

(X-L.sub.nz  General Formula (I)

X represents a formyl group, a boronic acid group, or a group represented by the following General Formula (I-B) or a group represented by the following General Formula (I-C), where L represents a single bond or divalent linking group, and n represents an integer equal to or greater than 2. When n is 2, Z represents a single bond or a divalent group, and when n≧3, Z represents an n-valent group.

##STR00001##

R.sup.A and R.sup.B represent an alkyl group, a cycloalkyl group, an aryl group, or an acyl group. R.sup.A and R.sup.B may be bonded to each other to form a ring. * represents a bond to be bonded to L.

In recognition of the need to develop novel therapeutic agents, the present invention provides novel histone deacetylase inhibitors. These compounds include an ester bond making them sensitive to deactivation by esterases. Therefore, these compounds are particularly useful in the treatment of skin disorders. When the compounds reaches the bloodstream, an esterase or an enzyme with esterase activity cleaves the compound into biologically inactive fragments or fragments with greatly reduced activity Ideally these degradation products exhibit a short serum and/or systemic half-life and are eliminated rapidly. These compounds and pharmaceutical compositions thereof are particularly useful in treating cutaneous T-cell lymphoma, neurofibromatosis, psoriasis, hair loss, skin pigmentation, and dermatitis, for example. The present invention also provides methods for preparing compounds of the invention and intermediates thereto.

In recognition of the need to develop novel therapeutic agents, the present invention provides novel histone deacetylase inhibitors. These compounds include an ester bond making them sensitive to deactivation by esterases. Therefore, these compounds are particularly useful in the treatment of skin disorders. When the compounds reaches the bloodstream, an esterase or an enzyme with esterase activity cleaves the compound into biologically inactive fragments or fragments with greatly reduced activity Ideally these degradation products exhibit a short serum and/or systemic half-life and are eliminated rapidly. These compounds and pharmaceutical compositions thereof are particularly useful in treating cutaneous T-cell lymphoma, neurofibromatosis, psoriasis, hair loss, skin pigmentation, and dermatitis, for example. The present invention also provides methods for preparing compounds of the invention and intermediates thereto.

The present invention relates to compounds effective in treating hepatotoxicity and fatty liver diseases and uses thereof. The present compound is represented by Formula (II), which has the formula: R.sub.1—O—X—(CH.sub.2).sub.m—X—O—R.sub.2, wherein: each X is —C(═O)—; R.sub.1 is a C.sub.1-C.sub.18 alkyl polyol; R.sub.2 is a saccharide group of formula (G).sub.p; G is a monosaccharide residue, where (i) at least one of the —OH groups in (G).sub.p is substituted by a halogen atom, and (ii) the saccharide group of formula (G).sub.p is linked to —O— through a —CH.sub.2 group; p is 1 or 2; and m is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.

The present invention relates to compounds effective in treating hepatotoxicity and fatty liver diseases and uses thereof. The present compound is represented by Formula (II), which has the formula: R.sub.1—O—X—(CH.sub.2).sub.m—X—O—R.sub.2, wherein: each X is —C(═O)—; R.sub.1 is a C.sub.1-C.sub.18 alkyl polyol; R.sub.2 is a saccharide group of formula (G).sub.p; G is a monosaccharide residue, where (i) at least one of the —OH groups in (G).sub.p is substituted by a halogen atom, and (ii) the saccharide group of formula (G).sub.p is linked to —O— through a —CH.sub.2 group; p is 1 or 2; and m is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.

A photoresist composition containing (A) a polymer having a structural unit (I) that includes an acid-labile group, and (I) a compound represented by the following formula (1). In the following formula (1), R.sup.1, R.sup.2, R.sup.3 and R represent a hydrogen atom or a monovalent organic group having 1 to 20 carbon atoms. X represents a single bond, an oxygen atom or —NR.sup.a—. R.sup.a represents a hydrogen atom, a hydroxy group or a monovalent organic group having 1 to 20 carbon atoms, and optionally taken together represents a ring structure by binding with R each other. A.sup.− represents —SO.sub.3.sup.− or —CO.sub.2.sup.−. M.sup.+ represents a monovalent onium cation. ##STR00001##